X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
MYK-461 (mavacamten) is the first and only cardiac myosin inhibitor, that demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy Chinese volunteers.
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: LianBio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2022
Details:
Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin being investigated for treatment of symptomatic obstructive HCM which is a progressive disease that thickens heart walls and makes it harder for the heart to expand normally and fill with blood.
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 21, 2022
Details:
The NDA submission was based on the results of the pivotal Phase 3 EXPLORER-HCM trial, which evaluated mavacamten in patients with symptomatic oHCM versus placebo.
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2021
Details:
Through the transaction with MyoKardia, Bristol Myers Squibb gains mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy, a chronic heart disease with high morbidity and patient impact.
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $13,100.0 million Upfront Cash: $13,100.0 million
Deal Type: Acquisition November 17, 2020
Details:
Mavacamten treatment resulted in favorable effect on cardiac structure -- significantly reduced hypertrophy in patients with hypertrophic cardiomyopathy.
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 15, 2020
Details:
MyoKardia and American College of Cardiology reported establishment of a nationwide registry of hypertrophic cardiomyopathy. The registry will support MyoKardia’s post-marketing safety and effectiveness study of mavacamten.
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: American College of Cardiology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 11, 2020
Details:
Two of the abstracts accepted for presentation focus on echocardiographic and cardiac magnetic resonance imaging (CMR) data from the pivotal EXPLORER-HCM clinical trial of mavacamten.
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
The acquisition provides Bristol Myers Squibb access to Mavacamten, a potential first-in-class myosin inhibitor with compelling data in the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy.
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $13,100.0 million Upfront Cash: $13,100.0 million
Deal Type: Acquisition October 05, 2020
Details:
First patient has been dosed in the company’s Phase 2 clinical trial of danicamtiv (formerly MYK-491) in people with primary dilated cardiomyopathy (DCM) thought to be caused by genetic mutations of the sarcomere.
Lead Product(s): Danicamtiv
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-491
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2020
Details:
The partnership will initially pursue a registration strategy for mavacamten in China for obstructive HCM, with plans for additional indications to follow, in keeping with MyoKardia’s development strategy.
Lead Product(s): Mavacamten
Therapeutic Area: Cardiology/Vascular Diseases Product Name: MYK-461
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: LianBio
Deal Size: $187.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
